Biogen Inc and Stoke Therapeutics Inc, a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, announced presentations of new clinical data… read more.
Ionis Pharmaceuticals,Inc. announced that the FDA has approved Dawnzera (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age… read more.
Bristol Myers Squibb announced the presentation of new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 29… read more.
BeOne Medicines Ltd. announced that the European Commission has approved a new film-coated tablet formulation of Brunkinsa (zanubrutinib) for all approved indications. “Developed to meet the real-world needs… read more.
Alkermes announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at World Sleep Congress, taking place… read more.
In its latest (Q2) earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly costs due to lower… read more.
Idorsia announced that The Galien Foundation, a premier global institution dedicated to honoring innovators in life sciences, has nominated Tryvio (aprocitentan) in the category of “Best Pharmaceutical Product”… read more.
Precigen, Inc. announced that the FDA has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). Papzimeosis the first and only FDA-approved therapy… read more.
Iovance Biotherapeutics Inc. announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Amtagvi (lifileucel), a tumor-derived autologous T cell immunotherapy. Amtagvi is indicated for… read more.
The FDA has updated Skysona’s indication, allowing it to be used only in patients who do not have an available human leukocyte antigen (HLA)-matched donor for stem cell… read more.
Novo Nordisk announced that the FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic… read more.
NICE (UK): Ruxolitinib cream is not recommended, within its marketing authorisation, for treating non-segmental vitiligo with facial involvement in people 12 years and over. This recommendation is not… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
